U.S. Imposes New Tariffs on Imported Pharmaceutical Drugs
美國對進口藥品加徵新關稅
On April 2, 2026, the U.S. government introduced a bold new policy to shift pharmaceutical manufacturing back to American soil.
2026年4月2日，美國政府推出一項大膽的新政策，旨在將藥品製造業遷回美國本土。
Citing national security concerns under Section 232 of the Trade Expansion Act, the administration announced significant tariffs on imported drugs.
基於1962年《貿易擴張法》(ㄇㄠˋ ㄧˋ ㄎㄨㄛˋ ㄓㄤ ㄈㄚˇ)第232條的國家安全考量，政府宣布對進口藥品徵收高額關稅。
While generic drugs, biosimilars, and veterinary medicines remain exempt, the policy creates a complex landscape for the pharmaceutical industry.
雖然學名藥、生物相似藥及獸藥保持豁免，但該政策為製藥產業創造了複雜的環境。
Strategic trade partners like the European Union, Japan, and Switzerland benefit from lower tariff caps, and a special agreement is in place for the United Kingdom.
歐盟、日本和瑞士等戰略貿易夥伴享有較低的關稅上限，且英國也訂有特別協議。
Supporters argue this initiative will stabilize supply chains and eventually lower drug costs for patients.
支持者認為，此舉將穩定供應鏈並最終降低患者的藥費。
However, the policy has sparked debate; critics worry that smaller biotech firms may struggle to survive under these new financial pressures, fearing that the regulations favor large, well-resourced corporations.
然而，該政策引發了辯論；批評者擔心小型生物科技公司可能在這些新的財政壓力下難以生存，擔憂監管規定偏袒資源豐富的大型企業。
